Specialty clinical-stage pharmaceutical company SciSparc Ltd. SPRC has entered into a merger agreement with AutoMax Motors Ltd., a vehicle importer company in Israel. Deal terms not disclosed.
The strategic move entails SciSparc securing full ownership of AutoMax and establishing a fresh subsidiary in Israel that will subsequently merge with AutoMax.
This merger aims to form a new entity with SciSparc shareholders owning slightly more than 50% of its capital, aligning with the company’s strategy to seek value-enhancing opportunities. SciSparc’s ongoing pharmaceutical operations will continue seamlessly after the merger.
Post-merger, AutoMax shares will convert to SciSparc ordinary share rights, with its stakeholders owning approximately 49.99% of the merged entity, subject to adjustments. SciSparc commits to a minimum of $4.25 million in net cash at deal closure.
Notably, both companies share a chairman Amitai Weiss, indicating a close relationship at the leadership level, underscoring the merger’s role in SciSparc’s diversification into the automotive industry.
Price Action: SPRC shares are trading higher by 6.88% at $1.79 on Thursday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image sourced from Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
